Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. We currently have a pipeline of product candidates in human clinical testing, including nine immuno-oncology programs. Our product candidates and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe.